Company: BLCO
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001860742-25-000018
Chunk: 78

Company: Bausch & Lomb Corp
Filing Date: 2025-07-30
Form: 10-Q
Item: Item 8
Chunk 78
---
 Segment RevenueThe Surgical segment revenue was $430 million and $406 million for the six months ended June 30, 2025 and 2024, respectively, an increase of $24 million, or 6%. The increase was primarily driven by: (i) increased demand of consumables, (ii) increased demand of implantables, driven by our premium IOL portfolio and (iii) increased equipment sales, partially offset by the voluntary recall of certain enVista IOL products, as previously discussed. This increase included: (i) incremental 

44

sales from acquisitions of $12 million, (ii) an increase in volumes of $8 million, (iii) an increase in net realized pricing of $3 million and (iv) the favorable impact of foreign currencies of $1 million.Cash Discounts and Allowances, Chargebacks and Distribution FeesProvisions recorded to reduce gross product sales to net product sales and revenues for the six months ended June 30, 2025 and 2024 were as follows:Six Months Ended June 30,20252024(in millions)AmountPct.AmountPct.Gross product sales$3,936 100.0 %$3,606 100.0 %Provisions to reduce gross product sales to net product salesDiscounts and allowances225 5.70 %208 5.80 %Returns32 0.80 %48 1.30 %Rebates932 23.70 %688 19.10 %Chargebacks295 7.50 %318 8.80 %Distribution fees47 1.20 %37 1.00 %Total provisions1,531 38.90 %1,299 36.00 %Net product sales2,405 61.10 %2,307 64.00 %Other revenues10 8 Revenues$2,415 $2,315 Cash discounts and allowances, returns, rebates, chargebacks and distribution fees as a percentage of gross product sales were 38.9% and 36.0% for the six months ended June 30, 2025 and 2024, respectively, an increase of 2.9% percentage points, and is primarily attributable to the increase in rebates from our dry eye portfolio, including XIIDRA® and MIEBO®.Operating ExpensesCost of Goods Sold (exclusive of amortization and impairments of intangible assets)